0
Following the European Medicines Agency’s (EMA) positive opinion of Rexatilux ranibizumab biosimilar in April 2026, on 21 May 2026, the EMA’s Committee for Medicinal Products for Human Use (CHMP) a...
More >- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
-
Biosimilars
News
- EMA recommends approval for ranibizumab biosimilar Vislyfa
- FDA approves third interchangeable insulin glargine biosimilar Langlara
- EMA recommends approval for ranibizumab biosimilar Rexatilux
- Japan approves Samsung-Nipro’s ustekinumab biosimilar
Research
- Biosimilars uptake in Chile: why does it lags behind?
- Biosimilar aflibercept (AVT06) pre-filled syringe promises safer, faster eye injections
- OECD study finds no direct link between advertising rules and biosimilar uptake
- Reaching ESG goals in pharmaceutical development
- MORE EDITORIAL SECTIONS
- Search
